Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada

INTRODUCTION: To evaluate the cost-effectiveness of evolocumab when added to standard of care lipid-lowering treatment (LLT) for patients with atherosclerotic cardiovascular disease (ASCVD) who cannot adequately control their low-density lipoprotein cholesterol (LDL-C) despite optimized LLT in Canad...

Descripción completa

Detalles Bibliográficos
Autores principales: Grégoire, Jean, Champsi, Salimah, Jobin, Manon, Martinez, Laura, Urbich, Michael, Rogoza, Raina M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239938/
https://www.ncbi.nlm.nih.gov/pubmed/35604523
http://dx.doi.org/10.1007/s12325-022-02130-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239938/
https://www.ncbi.nlm.nih.gov/pubmed/35604523
http://dx.doi.org/10.1007/s12325-022-02130-4

Ejemplares similares